DexCom, Inc. (NASDAQ:DXCM) Position Increased by GDS Wealth Management

GDS Wealth Management grew its position in DexCom, Inc. (NASDAQ:DXCM) by 41.7% in the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 54,770 shares of the medical device company’s stock after purchasing an additional 16,128 shares during the period. GDS Wealth Management’s holdings in DexCom were worth $6,210,000 at the end of the most recent quarter.

Other institutional investors have also made changes to their positions in the company. Vanguard Group Inc. lifted its position in shares of DexCom by 0.3% in the 1st quarter. Vanguard Group Inc. now owns 44,603,745 shares of the medical device company’s stock valued at $6,186,539,000 after acquiring an additional 136,282 shares in the last quarter. Capital Research Global Investors lifted its holdings in shares of DexCom by 21.4% in the fourth quarter. Capital Research Global Investors now owns 15,296,032 shares of the medical device company’s stock valued at $1,898,085,000 after purchasing an additional 2,695,296 shares in the last quarter. Sands Capital Management LLC boosted its position in shares of DexCom by 10.2% in the fourth quarter. Sands Capital Management LLC now owns 15,058,806 shares of the medical device company’s stock worth $1,868,647,000 after buying an additional 1,398,136 shares during the period. Capital World Investors boosted its position in shares of DexCom by 130.7% in the fourth quarter. Capital World Investors now owns 9,278,685 shares of the medical device company’s stock worth $1,151,392,000 after buying an additional 5,256,092 shares during the period. Finally, Artisan Partners Limited Partnership grew its holdings in shares of DexCom by 164.8% during the fourth quarter. Artisan Partners Limited Partnership now owns 5,900,308 shares of the medical device company’s stock valued at $732,169,000 after buying an additional 3,672,471 shares in the last quarter. 97.75% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other DexCom news, EVP Michael Jon Brown sold 659 shares of the stock in a transaction on Friday, June 28th. The stock was sold at an average price of $114.29, for a total transaction of $75,317.11. Following the completion of the transaction, the executive vice president now directly owns 66,901 shares in the company, valued at $7,646,115.29. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, EVP Sadie Stern sold 426 shares of DexCom stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $69.15, for a total value of $29,457.90. Following the completion of the transaction, the executive vice president now directly owns 75,451 shares of the company’s stock, valued at $5,217,436.65. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Michael Jon Brown sold 659 shares of the business’s stock in a transaction dated Friday, June 28th. The stock was sold at an average price of $114.29, for a total transaction of $75,317.11. Following the completion of the transaction, the executive vice president now directly owns 66,901 shares of the company’s stock, valued at $7,646,115.29. The disclosure for this sale can be found here. Insiders sold 2,483 shares of company stock worth $201,708 in the last 90 days. 0.30% of the stock is owned by company insiders.

DexCom Stock Performance

Shares of NASDAQ DXCM opened at $70.09 on Tuesday. The firm has a market capitalization of $27.87 billion, a price-to-earnings ratio of 45.22, a PEG ratio of 2.12 and a beta of 1.18. DexCom, Inc. has a one year low of $62.34 and a one year high of $142.00. The business has a fifty day simple moving average of $81.54 and a 200 day simple moving average of $110.92. The company has a current ratio of 2.82, a quick ratio of 2.48 and a debt-to-equity ratio of 1.00.

DexCom (NASDAQ:DXCM) last released its quarterly earnings data on Thursday, July 25th. The medical device company reported $0.43 EPS for the quarter, topping analysts’ consensus estimates of $0.39 by $0.04. The company had revenue of $1 billion during the quarter, compared to the consensus estimate of $1.04 billion. DexCom had a net margin of 16.95% and a return on equity of 31.41%. The firm’s revenue for the quarter was up 15.3% compared to the same quarter last year. During the same period last year, the firm earned $0.34 EPS. Sell-side analysts expect that DexCom, Inc. will post 1.69 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms recently commented on DXCM. BTIG Research decreased their price target on shares of DexCom from $156.00 to $120.00 and set a “buy” rating for the company in a report on Friday, July 26th. Wells Fargo & Company cut their price target on shares of DexCom from $145.00 to $80.00 and set an “overweight” rating on the stock in a report on Friday, July 26th. StockNews.com cut shares of DexCom from a “buy” rating to a “hold” rating in a report on Monday, June 10th. JPMorgan Chase & Co. lowered DexCom from an “overweight” rating to a “neutral” rating and cut their target price for the company from $145.00 to $75.00 in a report on Friday, July 26th. Finally, Morgan Stanley decreased their price target on DexCom from $120.00 to $75.00 and set an “equal weight” rating for the company in a research note on Friday, July 26th. Seven equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $112.25.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.